GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SRTOY) » Definitions » Cyclically Adjusted PS Ratio

SRTOY (Sartorius Stedim Biotech) Cyclically Adjusted PS Ratio : 7.35 (As of Jun. 01, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Sartorius Stedim Biotech Cyclically Adjusted PS Ratio?

As of today (2025-06-01), Sartorius Stedim Biotech's current share price is $21.39. Sartorius Stedim Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $2.91. Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio for today is 7.35.

The historical rank and industry rank for Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio or its related term are showing as below:

SRTOY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.1   Med: 10.52   Max: 20.9
Current: 7.66

During the past years, Sartorius Stedim Biotech's highest Cyclically Adjusted PS Ratio was 20.90. The lowest was 6.10. And the median was 10.52.

SRTOY's Cyclically Adjusted PS Ratio is ranked worse than
81.88% of 480 companies
in the Medical Devices & Instruments industry
Industry Median: 2.23 vs SRTOY: 7.66

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sartorius Stedim Biotech's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.828. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.91 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Chart

Sartorius Stedim Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 14.68 10.46 7.53

Sartorius Stedim Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.36 6.36 7.75 7.53 7.20

Competitive Comparison of Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio falls into.


;
;

Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=21.39/2.91
=7.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Sartorius Stedim Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.828/127.7792*127.7792
=0.828

Current CPI (Mar. 2025) = 127.7792.

Sartorius Stedim Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201306 0.221 98.516 0.287
201312 0.000 99.356 0.000
201406 0.251 99.543 0.322
201412 0.000 99.543 0.000
201506 0.261 100.417 0.332
201512 0.000 99.717 0.000
201606 0.323 100.717 0.410
201612 0.000 101.217 0.000
201706 0.334 102.117 0.418
201709 0.331 102.717 0.412
201712 0.355 102.617 0.442
201803 0.373 102.917 0.463
201806 0.384 104.017 0.472
201809 0.396 104.718 0.483
201812 0.393 104.217 0.482
201903 0.421 104.217 0.516
201906 0.447 105.718 0.540
201909 0.436 106.018 0.525
201912 0.437 105.818 0.528
202003 0.506 105.718 0.612
202006 0.546 106.618 0.654
202009 0.651 105.818 0.786
202012 0.703 105.518 0.851
202103 0.843 107.518 1.002
202106 0.910 108.486 1.072
202109 0.964 109.435 1.126
202112 0.954 110.384 1.104
202203 1.030 113.968 1.155
202206 0.988 115.760 1.091
202209 0.945 118.818 1.016
202212 1.023 119.345 1.095
202303 0.847 122.402 0.884
202306 0.792 123.140 0.822
202309 0.766 124.195 0.788
202312 0.839 123.773 0.866
202403 0.745 125.038 0.761
202406 0.799 125.882 0.811
202409 0.742 126.198 0.751
202412 0.809 127.041 0.814
202503 0.828 127.779 0.828

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sartorius Stedim Biotech  (OTCPK:SRTOY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius Stedim Biotech Business Description

Address
Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.